Objectives. Patient acceptable symptom state (PASS) as an absolute state of well-being has shown promise as an outcome measure in many rheumatologic conditions. We aimed to assess whether PASS may be effective in active diffuse cutaneous SSc differentiating active from placebo.
Introduction
SSc is a rare connective tissue disease that is characterized by fibrosis, inflammation and vascular damage. Clinical presentations are heterogeneous in nature, affecting the skin as well as pulmonary, cardiac, renal and gastrointestinal systems. dcSSc has a high mortality [1] . Clinical trials are ongoing to search for more effective treatment options, with the Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis (faSScinate) trial assessing the effectiveness of tocilizumab (TCZ), a novel IL-6 antibody in a randomized placebo-controlled trial in dcSSc [2] .
Designing effective clinical trials in SSc has many challenges, which is due in part to the paucity of previous positive studies in SSc [2] . The heterogeneity of the disease along with its varying clinical presentation makes it difficult to identify what outcome measures to assess. Often the modified Rodnan skin score (mRSS) is a primary endpoint [3] . Patient-reported outcomes have been used as a means of understanding what patients' view as a satisfactory response to therapy. The concept of minimal clinically important difference has been seen as a helpful way to provide complementary and more meaningful information to the endpoints of a trial [4, 5] . However, Tubach et al. [6] have shown that patients care more about feeling good than they do about feeling better. For instance, if there is a large change in status but a patient is still in a moderate state of activity, this is not preferred, as the goal is likely to feel good, not to benchmark feeling better than a previous state.
Patient acceptable symptom state (PASS) is an outcome measure that allows for assessing either when patients feel good or when patients feel better. The OMERACT meeting in 2007 established the concept of PASS, however, there has been no standardized question across diseases [5] . Achieving a PASS depends on how this question is asked, but generally it is used to describe the point beyond which patients consider themselves well [7] . The aim of introducing PASS is to provide a means to translate a holistic look at patients' symptoms into more clinically meaningful information.
PASS has been demonstrated to be an effective assessment and robust marker in many rheumatologic diseases [811], although it is yet to be evaluated in SSc. Our aim was to assess the effectiveness of PASS as an outcome marker for SSc using patients from the faSScinate trial, including relationships to other outcomes and if and when it could differentiate active treatment from placebo.
Methods

Study population
This study uses data collected from patients enrolled in the faSScinate trial (NCT01532869), which is outlined in detail by Khanna et [12] and active dcSSc subset. Patients were randomized to TCZ 162 mg s.c. weekly or placebo and were assessed at regular intervals. The primary outcome was mRSS assessed at 24 weeks. At 24 weeks, the treating physician could place patients on rescue medication as deemed necessary, while all patients could be transitioned to TCZ at 48 weeks. While the results for the primary outcome resulted in a negative study, there was a clinically meaningful decline in mRSS over 48 weeks in the TCZ group compared with the placebo group as determined by the minimal clinically important difference. Each site's institutional review board or ethics committee approved the protocol before the study commenced. The study was done in accordance with the Declaration of Helsinki and Good Clinical Practice. The questionnaires were approved as part of the case report forms of the trial.
PASS
There has been no standardized question as to the best way to ask a patient whether they are in an acceptable symptom state [13] . Previous studies have evaluated dichotomous and scaled patient-reported outcomes as well as statistical approaches to define PASS [5, 810] . We evaluated three questions that considered dichotomous vs scaled outcomes as well as the acceptability of symptoms vs changes to baseline. PASS 1 was aimed at assessing the level of acceptability of symptoms based on a scale: 'Considering all of the ways your scleroderma has affected you over the last week, how acceptable would you rate your level of symptoms?' Responses were reported on a 7-point Likert scale with choices ranging from À3 (highly unacceptable) to 3 (highly acceptable).
PASS 2 used the level of acceptability as a dichotomous outcome: 'Think about all the ways that your scleroderma has affected you during the last week. If you were to remain for the next few months as you were in the last week, would this be acceptable to you?' Responses were reported as either yes or no.
PASS 3 asked about a change in symptoms: 'Has there been a change in how you would describe your level of functional impairment since you started the study?' Responses were reported on a 5-pont Likert scale with choices ranging from À2 (much worse) to 0 (no change) to 2 (much better).
Outcomes assessed
Khanna et al. [14] recently provided suggestions as to the most relevant disease outcome markers to consider in trials on SSc. These included mRSS, percent predicted of forced vital capacity, physician global assessment [physician global visual analogue scale (VAS)], patient global assessment (patient global VAS) and the HAQ disability index (HAQ-DI). We considered all of these outcomes with the exception of the percent predicted of forced vital capacity, as successful treatment is expected to slow the progression of lung disease rather than lead to improvement in symptoms. Additionally, we included CRP and ESR to assess systemic inflammation. Patients were evaluated at weeks 8, 24, 48 and 96.
Statistical analysis
Normality for each of the outcome markers was assessed using the ShapiroWilk test. Patient characteristics were analysed using independent samples t-tests with twotailed P-values. The proportion of patients achieving PASS 1 and 3 was considered as a 1-point increase from their baseline visit score, whereas PASS 2 was having a response of 'yes'. Correlations were assessed using Goodman and Kruskal's g value due to the many tied ranks with respect to the PASS questions and other outcomes at weeks 8, 24, 48 and 96. Determining the significance of PASS in differentiating patients on TCZ vs placebo was done using the Pearson 2 value. Pvalues <0.05 were considered significant. All analyses were carried out using SPSS version 24 (IBM, Armonk, NY, USA).
Results
Patient characteristics comparing placebo vs TCZ are presented in Table 1 . There were 44 patients at baseline in the placebo group and 43 patients in the TCZ group. At baseline, PASS 1 had 32 (73%) and 35 (81%) patients scoring 40 for placebo and TCZ, respectively. PASS 2 had 28 (64%) and 29 (69%) patients responding with a 'no' for placebo and TCZ, respectively. PASS 3 was designed to have a baseline of 0 suggesting no change, however, only 36 (82%) and 32 (74%) patients responded with a baseline score of 0 for placebo and TCZ, respectively. There were no reports of patients refusing to answer. All outcomes were non-normally distributed with the exception of age and mRSS. A greater number of patients were discontinued from the trial in the placebo group (n = 20) vs the TCZ group (n = 16), but with no statistical significance identified. Similarly, 9 (28%) patients required rescue meds in the placebo group compared with 3 (10%) in the TCZ group between 24 and 48 weeks, but without statistical significance. Baseline characteristics were similar between the active and placebo groups [2] .
The three PASS questions are evaluated and compared in Table 2 . The proportion of patients achieving PASS increased for all three questions as the trial progressed, with the proportions being similar across all three questionnaires at each visit. The majority of patients had achieved PASS by the end of the trial (69, 71 and 78% for PASS 1, 2 and 3, respectively).
PASS 1 at 48 weeks showed statistical significance in being able to differentiate those patients on placebo vs TCZ (P = 0.023), where a 51 point change on the Likert scale could differentiate TCZ from placebo. The patient global VAS and HAQ-DI score showed a moderately negative correlation across all three PASS questions. The physician global VAS also showed a moderately negative correlation that was statistically significant for PASS 2 and 3. Total mRSS, CRP and ESR did not show a correlation with any of the PASS questions.
Discussion
This article is the first to assess the usefulness of PASS in a randomized controlled trial (RCT) in SSc. We found that the majority of patients in the faSScinate study had achieved PASS by the end of the trial. Given the clinically Evaluating PASS in trials involving SSc appears to be a reliable means of complementing primary endpoints of studies by weighing the benefits or harms that patients may experience from therapy. As a result, PASS has the benefit of being able to translate results from large trials to an individual level, thus providing further guidance for patient decisions [7] . No patients refused to answer PASS, which, along with previous studies, suggests its acceptability [8] .
The PASS questions were moderately correlated with the HAQ-DI score, patient global VAS and physician global VAS. This means that as disease outcomes improve, patients are more likely to enter into an acceptable symptom state. When assessing active dcSSc and drugs to improve skin and overall disease, it is not likely that most treatments will improve the gastrointestinal involvement, Raynaud's and other symptoms when softening skin and/or targeting lung function. Asking a PASS question is a holistic way to determine whether the treatment is improving the patient's quality of life overall. Patients likely consider the benefit of treatment, the side effects and their SSc symptoms together. The moderate correlation identifies that PASS is sufficiently different from these outcomes, suggesting that it may consider additional aspects of a patient's disease state that our current outcome markers do not evaluate. Despite mRSS being the primary endpoint in many SSc trials [3] , including the faSScinate trial [2], there was no correlation seen with PASS. This suggests that mRSS complements patient-reported outcome measures and may actually play a smaller role in affecting the patient's symptom state than previously expected, at least for the degree of skin improvement that occurs during an RCT where the change is modest. An example of this is that hand function is often still quite impaired, as skin tends to soften more in proximal areas first.
Our findings support the use of PASS 1 in future clinical trials. Although an improvement of 1 point does not indicate whether patients have reached an absolute acceptable symptom state, it does serve to distinguish TCZ vs placebo, which can be used as an endpoint in future clinical trials. Whereas PASS 2 only showed a trend towards statistical significance, it could serve as a reasonable alternative given its validation in previous trials [8, 15] . The simple dichotomous outcome does indicate whether patients have reached an absolute acceptable symptom state, but concerns arise due to a loss of statistical power in what is already a rare disease [5] . We would advise against using PASS 3, given the lack of statistical significance and patients misinterpreting the question.
Although achieving PASS suggests a state of wellbeing, it is not synonymous with achieving perfect health [16] . PASS 1 helps to instruct clinicians as to when their patients feel better from treatment. Conversely, PASS 2 gives clinicians a sense of when patients feel good and reach a level of contentment with their current symptoms. PASS 1 and 2 ask about current state acceptability, whereas PASS 3 is a change in state. The first two are an absolute state. It is difficult to interpret what it means to achieve a PASS to a patient with SSc and their treating physician.
There are inherent limitations in an exploratory analysis. When evaluating patients at 48 weeks, a disproportionate number of patients between the placebo and TCZ groups Values were calculated using Goodman and Kruskal's g. Negative value indicates a negative correlation, in which a decrease in relative relates with improvement in the PASS score.
received rescue medication, possibly limiting the ability of PASS to differentiate placebo vs TCZ. For the patients remaining in the study up to 96 weeks (in the open-label extension between 48 and 96 weeks), more patients entered into an acceptable symptom state, so a longer duration of placebo vs TCZ may have provided more power to differentiate the two groups. Raynaud's and gastrointestinal symptoms are examples of symptoms that may be strongly correlated with patients achieving PASS or not, which this study did not evaluate.
Conclusion
In summary, PASS may be used as an effective outcome marker in SSc. PASS is likely to be most effective when evaluating the acceptability of symptoms based on a 7-point Likert scale. Further validation of PASS in clinical trials and practice in SSc is required to determine whether the findings of this study are consistent. 
